Image credit- shutterstock
Sisram Medical, a global wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, has announced that its wholly-owned subsidiary, Sisram Medical China (Tianjin) has entered into a Memorandum of Understanding (MoU) with Sinmait Medical Technology (Beijing), a subsidiary of Shanghai Fosun Pharmaceutical (Group). This MoU establishes a framework for cooperation aimed at enhancing localization efforts in China.
This partnership is poised to accelerate Sisram's strategic implementation and business expansion in the Chinese market, strengthen the resilience of its global supply chain, and solidify the Company's position as a leader in innovation and market presence in medical aesthetics, both locally and globally.
By deepening its partnership with Fosun Pharma, Sisram will leverage Sinmait's advanced production capabilities and local expertise to establish a robust manufacturing hub in China, initially focused on localized production of Energy-Based Devices (EBD) and setting the stage for expansion into a broader product portfolio.
The new facility will cater to domestic demand and serve as a strategic center for the APAC region, addressing the growing need for scalable production, sophisticated logistics, and advanced research and development.
As combined therapies gain traction in China's medical aesthetics sector, the synergistic development and localized manufacturing of EBD alongside other product offerings will significantly enhance the portfolio's overall effectiveness, providing Chinese consumers with a wider array of superior and accessible domestic wellness solutions.
